预约演示
更新于：2026-01-28
Forodesine Hydrochloride
呋咯地辛
更新于：2026-01-28
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2017-03-31), |
最高研发阶段(中国)- |
特殊审评孤儿药 (欧盟)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C11H15ClN4O4 |
InChIKeyWEIAMZKHBCLFOG-QPAIBFMUSA-N |
CAS号284490-13-7 |
关联
15
项与 呋咯地辛 相关的临床试验NCT01776411
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
JPRN-jRCT2080221940
Phase 1/2 clinical study of forodesine in Japanese recurrent/refractory peripheral T-cell lymphoma
NCT00742495
A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.
100 项与 呋咯地辛 相关的临床结果
登录后查看更多信息
100 项与 呋咯地辛 相关的转化医学
登录后查看更多信息
100 项与 呋咯地辛 相关的专利（医药）
登录后查看更多信息
227
项与 呋咯地辛 相关的文献（医药）2026-02-01Journal of NeuroInterventional Surgery
Multicenter analysis of flow diversion for recurrent/persistent intracranial aneurysms after stent-assisted coiling
Article
作者: Spiotta, Alejandro M ; Lylyk, Pedro ; Helal, Ahmed ; Kan, Peter ; Levy, Elad I ; Tanweer, Omar ; Burkhardt, Jan Karl ; Salih, Mira ; Gajjar, Avi A ; Sioutas, Georgios ; Park, Min S ; Hanel, Ricardo ; Levine, Alex ; Brinjikji, Waleed ; Srinivasan, Visish M ; Heiferman, Daniel M ; Salem, Mohamed M ; Levitt, Michael R ; Monteiro, Andre ; Saber, Hamidreza ; Hassan, Ameer E ; Tjoumakaris, Stavropoula I ; Albuquerque, Felipe C ; Jabbour, Pascal ; Starke, Robert M ; Wolfe, Stacey Q ; Colby, Geoffrey P ; Abbas, Rawad ; Lylyk, Ivan ; Limbucci, Nicola ; El Naamani, Kareem ; Abdelsalam, Ahmed ; Desai, Sohum ; Lanzino, Giuseppe ; Riina, Howard ; Kim, Louis J ; Renieri, Leonardo ; Catapano, Joshua S ; Raz, Eytan ; Ares, William J ; Jankowitz, Brian ; Arthur, Adam S ; Thomas, Ajith J ; Siddiqui, Adnan H ; Ogilvy, Christopher S ; Lopes, Demetrius Klee ; Ducruet, Andrew F ; Dumont, Aaron S ; Borg, Nicholas ; Nelson, Peter Kim ; Shapiro, Maskim
Background:
Flow-diverter stents (FDS) have become the standard of care for a wide range of intracranial aneurysms, but their efficacy/safety in the context of recurrent/recanalized aneurysms following stent-assisted coiling (SAC) is not well established. We evaluate the outcomes of FDS retreatment in a large multicenter cohort.
Methods:
We retrospectively analyzed data from 118 patients across 22 institutions who underwent FDS retreatment for recurrent/persistent aneurysms after SAC (2008–22). The primary outcome was angiographic occlusion status at last follow-up, categorized as complete (100%), near-complete (90–99%), or incomplete (<90%) occlusion. Secondary outcomes included procedural complications and clinical outcomes measured by the modified Rankin Scale (mRS).
Results:
A total of 118 patients (median age 57, 74.6% female) with median follow-up of 15.3 months were identified. Complete occlusion was achieved in 62.5% and near-complete occlusion in 25%. FDS deployment within the pre-existing stent was successful in 98.3% of cases. Major complications occurred in 3.4% of cases, including postoperative aneurysmal rupture with resultant mortality (1.6%) and thromboembolic events with long-term disability (1.6%). Favorable clinical outcomes (mRS 0–2) were observed in 95.1% of patients. Wider aneurysm neck diameter was a significant predictor of incomplete occlusion (adjusted OR (aOR) 1.23 per mm, P=0.044), with male sex trending towards association with non-occlusion (aOR 3.2, P=0.07), while baseline hypertension was associated with complete occlusion (aOR 0.32, P=0.048).
Conclusions:
FDS treatment for recurrent/residual aneurysms after SAC represents a viable treatment option for these challenging cases with acceptable safety and reasonable occlusion rates, although lower than de novo FDS occlusion rates.
2026-01-01AMERICAN JOURNAL OF NEURORADIOLOGY
Efficacy and Safety of Flow Diversion for Distal Anterior Cerebral Aneurysms: A Systematic Review and Proportional Meta-Analysis
Review
作者: Cardoso, Leonardo Januario Campos ; Consoli, Arturo ; Alexandre, Andrea M ; Elek, Alperen ; Pereira, Vitor M ; Günkan, Ahmet ; Scarcia, Luca ; Onal, Yilmaz ; Vilardo, Marina ; Bocanegra-Becerra, Jhon E ; Dmytriw, Adam Andrew ; Scarramal, João Paulo Liute ; Wintermark, Max ; Clarençon, Frédéric ; Salim, Hamza
BACKGROUND:
Flow diverters (FDs) are increasingly used off-label for the treatment of distal anterior cerebral artery aneurysms (DACAAs), located at or beyond the A2 segment of the anterior cerebral artery (ACA). However, data on safety and efficacy remain limited.
PURPOSE:
To evaluate the safety and efficacy of FDs for the treatment of DACAAs through a systematic review and meta-analysis.
DATA SOURCES:
PubMed, Scopus, and Web of Science were systematically searched according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.
STUDY SELECTION:
Studies were eligible if they reported on ≥5 patients treated with FDs for DACAAs and provided angiographic and clinical outcome data.
DATA ANALYSIS:
Efficacy outcomes included adequate and complete aneurysm occlusion rates and re-treatment rates. Safety outcomes included good functional outcome (mRS 0-2), procedure-related morbidity and mortality, procedure-related complications, in-stent stenosis, and covered branch occlusion. Pooled estimates with 95% CIs were calculated by using a random-effects model.
DATA SYNTHESIS:
Eleven retrospective studies comprising 326 patients (71% women; mean age, 59.4 ± 4.4 years) with 328 DACAAs were included. Most aneurysms were unruptured (95.7%) and located in the A2 or A2-A3 segments (89%). Adequate and complete occlusion at last follow-up were 89% (95% CI, 82-96) and 77% (95% CI, 69-85), respectively. The re-treatment rate was 1% (95% CI, 0-3). Good functional outcome was reported in 97% (95% CI, 95-100). Procedure-related complications occurred in 7% (95% CI, 1-12), resulting in 1% morbidity (95% CI, 0-3) and no procedure-related deaths. In-stent stenosis and covered branch occlusion were observed in 4% (95% CI, 0-10) and 10% (95% CI, 6-13), respectively. Clinically symptomatic covered branch occlusion was rare (1.1%), possibly reflecting the adequacy of collateral circulation in distal ACA territory.
LIMITATIONS:
The analysis is based on retrospective studies that lacked centralized adjudication of angiographic outcomes, potentially introducing methodologic biases intrinsic to such study designs, including selection bias, confounding, and publication bias.
CONCLUSIONS:
FDs appear to be a safe and effective treatment option for DACAAs, with high rates of occlusion and favorable clinical outcomes, and low rates of re-treatment and procedure-related complications.
2025-09-28Journal of Clinical and Experimental Hematopathology
A therapeutic effect of Forodesine for CNS relapsed primary testicular T cell lymphoma after allogeneic transplantation
Article
作者: Tsutsumi, Hiroki ; Kudo, Masahisa ; Kobayashi, Hirofumi ; Maseki, Nobuo ; Sekiguchi, Yasunobu
Most primary testicular malignant lymphomas are derived from B-cell, with only a few cases of T-cell origin (primary testicular T cell lymphoma; PTTCL). In this report, we present a case of PTTCL who relapsed simultaneously in the central nervous system (CNS) and peripheral nerves, which was managed by allogeneic hematopoietic stem cell transplantation, but recurred again in the CNS. Treatment with the purine nucleotide phosphorylase inhibitor Forodesine achieved a therapeutic response. This finding suggests that Forodesine might be useful as a treatment option for CNS relapse in heavily treated T-cell lymphoma.
1
项与 呋咯地辛 相关的新闻（医药）2023-02-01
·生物谷
细胞疗法免疫疗法
100 项与 呋咯地辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周T细胞淋巴瘤 | 日本 | 2017-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 奥地利 | 2009-03-01 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 捷克 | 2009-03-01 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 法国 | 2009-03-01 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 德国 | 2009-03-01 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 意大利 | 2009-03-01 | |
| 前体B细胞成淋巴细胞白血病淋巴瘤 | 临床2期 | 英国 | 2009-03-01 | |
| 难治性 T 急性淋巴细胞白血病 | 临床2期 | 奥地利 | 2009-03-01 | |
| 难治性 T 急性淋巴细胞白血病 | 临床2期 | 捷克 | 2009-03-01 | |
| 难治性 T 急性淋巴细胞白血病 | 临床2期 | 法国 | 2009-03-01 | |
| 难治性 T 急性淋巴细胞白血病 | 临床2期 | 德国 | 2009-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 外周T细胞淋巴瘤 二线 | 48 | 鹽齋獵鬱構顧襯製艱網(築襯鏇鹽糧積網艱顧選) = 鬱顧艱糧獵膚衊鹽網鏇 醖膚齋壓選選淵淵衊襯 (齋顧範蓋壓膚夢窪壓獵, 14 ~ 38) 更多 | 积极 | 2019-01-01 | ||
临床1/2期 | 44 | 顧鏇夢選簾淵鏇艱蓋鏇(繭壓觸艱選積獵簾製鹹) = 願範憲願鑰鏇齋鏇繭夢 膚願簾艱顧願積壓齋願 (製壓窪艱積壓網積衊範, 12.0 ~ 35.3) 更多 | 积极 | 2016-05-20 | |||
临床2期 | 144 | 蓋糧築網憲遞膚構築獵(衊醖醖鑰鏇壓廠襯鑰齋) = 夢繭鬱範構製蓋繭範顧 範鬱獵選鹹憲築鑰簾襯 (糧壓簾鑰夢遞糧壓鹹醖 ) 更多 | - | 2014-09-01 | |||
临床2期 | 8 | Oral forodesine 200 mg/d | 窪壓壓膚憲壓構醖鑰顧(糧鑰衊襯選壓憲糧製繭) = 壓齋膚選繭壓膚顧鏇觸 鑰夢廠鏇選顧膚廠窪繭 (繭鏇鬱範壓範築憲簾醖 ) 更多 | - | 2010-08-12 | ||
N/A | 64 | 淵夢遞觸鹹繭遞獵衊選(蓋鑰網鹹遞醖襯鹹壓鏇) = 壓糧窪鏇遞艱構鏇膚膚 範膚構憲憲鑰餘繭蓋壓 (鏇鬱鏇製夢觸鏇鑰襯製 ) 更多 | - | 2009-05-20 | |||
临床1/2期 | 12 | 顧壓獵餘繭膚選獵簾築(廠願壓獵簾構築膚膚窪) = 繭遞製淵顧選齋簾餘糧 鹽遞構繭製鏇積積壓壓 (構膚繭襯簾積範築網憲 ) | - | 2005-11-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用